Meta‐analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma

Summary Background The use of sirolimus (SRL)‐based immunosuppression protocols have been reported to reduce recurrence rates following liver transplantation (LT) for hepatocellular carcinoma (HCC), although this is still a matter for debate. Aim To undertake a systematic review and meta‐analysis of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2013-02, Vol.37 (4), p.411-419
Hauptverfasser: Menon, K. V., Hakeem, A. R., Heaton, N. D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background The use of sirolimus (SRL)‐based immunosuppression protocols have been reported to reduce recurrence rates following liver transplantation (LT) for hepatocellular carcinoma (HCC), although this is still a matter for debate. Aim To undertake a systematic review and meta‐analysis of available literature on the usage of SRL as an immunosuppressive agent following LT for HCC, with a view to comparing cancer outcomes with the commonly used calcineurin inhibitors (CNIs). Methods Systematic review and meta‐analysis carried out in line with the Meta‐analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. Primary outcomes of interest were tumour recurrence rate and recurrence‐free survival (RFS). Secondary outcomes were recurrence‐related mortality and overall survival (OS). Results In all, 5 studies met the inclusion criteria (n = 474). The recurrence rate was lower in SRL group (4.9–12.9%) in comparison with CNIs (17.3–38.7%). The 1‐, 3‐ and 5‐year RFS was 93–96%, 82–86% and 79–80% for SRL group, which was much better in comparison with the CNIs 70–78%, 64–65% and 54–60% respectively. Similarly, 1‐, 3‐ and 5‐year OS was much better for SRL group (94–95%, 85% and 80%) in comparison with CNIs (79–83%, 66% and 59–62%) respectively. Meta‐analysis demonstrated lower recurrence (OR = 0.30, 95% CI = 0.16–0.55, P 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.12185